

Bibliography

1. MacMahon S. et al. Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet*. 1990; 335:765-774.
2. Collins R. et al. Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. *Lancet*. 1990; 335:827-838.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA*. 1991; 265, (24):3255-3264.
4. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a Working Group report from the National High Blood Pressure Education Program. *Pediatrics*. 1996; 98, (4):649-658.
5. Psaty BM et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis. *JAMA*. 1997; 277, (9):739-745.
6. Staessen J et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet*. 1997; 350:757-764.
7. Hansson L et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*. 1999; 354:1751-1756.
8. ALLHAT Officers. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2000; 283, (15):1967-1975.
9. Staessen J et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet*. 2000; 355:865-872.

10. Grimm RH et al. Baseline characteristics of participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension*. 2001; 37:19-27.
11. ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic; The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002; 288, (23):2981-2997.
12. Dahlöf B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet*. 2002; 359:995-1003.
13. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002; 360:1903-1913.
14. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. *Lancet*. 2003; 362:1527-1535.
15. Lindon MH et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med*. 2003; 348:583-92.
16. Psaty BM et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. *JAMA*. 2003; 289:2534-2544.
17. Staessen JA et al. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 *Journal of Hypertension*. 2003; 21:1055-1076.
18. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *Journal of Hypertension*. 2003; 21:1011-1053.
19. Nawrot TS et al. Should pulse pressure become part of the Framingham risk score? *Journal of Human Hypertension*. 2003; 18:279-286.
20. Volpe M et al. Beyond hypertension: Toward guidelines for cardiovascular risk reduction. *Am J Hypertens*. 2004; 17:1068-1074.

21. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2004.
22. Williams B. Recent hypertension trials: Implications and controversies. *J Am Coll Cardiol.* 2004; 45:813-827
23. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. 2005.
24. Cohn, J et al. Screening for Early Detection of Cardiovascular Disease in Asymptomatic Individuals. *American Heart Journal.* 2003; 679-685.
25. Cohn, J et al. Arterial Elasticity as Part of a Comprehensive Assessment of Cardiovascular Risk and Drug Treatment. *Hypertension.* 2005; 45:1-4.
26. Cohn, J. Arteries, Myocardium, Blood Pressure and Cardiovascular Risk: Towards a Revised Definition of Hypertension. *Journal of Hypertension.* 1998;(16)12:2117-2124.